Kalytera Therapeutics, Inc. (TSX VENTURE:KALY) (OTCQB:KALTF) (the
"
Company" or "
Kalytera") today
announced the formation of a Strategic & Scientific
Advisory Board with three key appointments: Professor Joseph Lynch,
Ph.D.; Dr. Li Zhang; and Professor Hanns Ulrich Zeilhofer.
The Strategic and Scientific Advisory Board will work
closely with Kalytera’s management to advance the Company’s novel
cannabinoid-based technology for the treatment of acute and chronic
pain, identify new applications for Kalytera’s cannabinoid
technology, and provide insight regarding new cannabinoid-based
technologies to complement the Company’s pipeline.
"We are thrilled to have attracted some of the world's leading
experts in pain to our Strategic and Scientific Advisory Board,"
said Robert Farrell, Kalytera’s President and Chief Executive
Officer. "The formation of our SSAB further validates the
scientific and clinical merit for our pain product and our pipeline
of CBD based pharmaceuticals."
Professor Joseph Lynch, Ph.D.Dr. Lynch
completed a BSc majoring in Physics at the University of Melbourne.
He then moved to the University of New South Wales to undertake a
Masters of Biomedical Engineering, and then a Ph.D. in Physiology.
His postdoctoral studies were undertaken in Germany, France and at
the Garvan Institute of Medical Research in Sydney. He moved to
University of Queensland in 1996 as a Senior Lecturer in the School
of Biomedical Sciences, and was awarded an NHMRC Senior Research
Fellowship in 2004 (renewed in 2009). He relocated to the
Queensland Brain Institute in October 2007.
Dr. Li ZhangDr. Zhang has worked as an NIH
Staff Scientist in the Laboratory for Integrative Neuroscience
since 2004. He is an expert in neuropharmacology, and has published
in Nature Chemistry and Biology, including a paper entitled
“Cannabinoid potentiation of glycine receptors contributes to
cannabis-induced analgesia.” Kalytera’s novel, proprietary
cannabinoid-naproxen conjugate is based in part on Dr. Zhang’s
pioneering research demonstrating that cannabinoids suppress
inflammatory and neuropathic pain by targeting alpha3 glycine
receptors.
Professor Hanns Ulrich
ZeilhoferDr. Zeilhofer studied medicine at the University
of Erlangen in Germany. He did his postdoctoral training at the
University of Erlangen, the Max Planck Institute for Biophysical
Chemistry and at ETH Zürich. From 2001 to 2005 he was associate
professor of Molecular Neuropharmacology at the Institute of
Experimental and Clinical Pharmacology and Toxicology, University
of Erlangen. In September 2005 he joined the Institute of
Pharmacology and Toxicology, University of Zurich, and, in
addition, in January 2016, the Swiss Federal Institute of
Technology (ETH) Zurich, as a full professor of pharmacology.
He currently serves as the director of the Institute of
Pharmacology and Toxicology of the University of Zurich and as a
member of the research council of the Swiss National Science
Foundation. He is also a founding member of the Drug Discovery
Network Zurich (DDNZ). His research has been supported by grants
from the European Research Council (ERC), the Swiss National
Science Foundation and the Wellcome Trust, among others. His
research has led to the identification of alpha3 glycine
receptors as promising targets in chronic pain conditions. Dr.
Zeilhofer has received scientific prizes from the SANDOZ-Foundation
for Therapeutic Research, the German Association for the Study of
Pain, the Sertürner Society and the PHOENIX Pharmacy award.
"The background and experience of these three experts will be
invaluable as we move through IND-enabling studies toward initial
clinical testing,” stated Farrell. “A major focus of their research
has been the molecular structure and function of the alpha3
glycine receptor that mediates inhibitory neurotransmission in
the brain. Kalytera’s cannabinoid-naproxen conjugate is intended to
target the alpha3 glycine pain receptor, which has recently emerged
as a promising therapeutic target for pain. Drs. Lynch, Zhang and
Zeilhofer are leaders in this field of research, and I am very
proud to have them join us as founding members of our Strategic
& Scientific Advisory Board established in connection with this
novel cannabinoid-based technology for the treatment of pain.”
About Kalytera’s
Product in Development for Treatment of
PainKalytera’s compound in development for treatment of
pain consists of a cannabinoid conjugated with naproxen, a generic,
non-steroidal, anti-inflammatory drug that is already approved for
treatment of pain. This cannabinoid/naproxen conjugate has
potential to become a next generation pain medication, and, based
on the potentially complementary methods of action of the
cannabinoid and naproxen, there is reason to believe these
molecules may have a synergistic effect in treatment of pain, as
well as a superior safety profile compared with opioid
analgesics.
The objective of Kalytera’s program is to develop a potent,
non-psychotropic, oral analgesic for intractable pain that will be
safe and well tolerated. The cannabinoid component will act as a
cannabinoid receptor agonist, targeting the alpha3 glycine pain
receptor in the spinal cord, and the naproxen component will block
the synthesis of the pain-inducing molecule PGE2. Although the
initial route of administration will be oral, Kalytera will also
seek to develop an intravenous formulation.
The commercial opportunity for Kalytera’s cannabinoid/naproxen
conjugate is large. According to a 2016 report by Transparency
Market Research, the global pain management therapeutics market is
projected to reach $83 billion by 2024. Current treatments for pain
mainly include non-steroidal anti-inflammatory drugs ("NSAIDs"),
such as naproxen, for mild to moderate pain, and opioids, such as
morphine, for moderate to severe and chronic pain. Kalytera
believes that its product will be suitable for mild to severe pain,
without the risks of respiratory suppression and dependence
associated with opioid analgesics.
Kalytera’s strategy will be to advance this compound through
Phase 1 and Phase 2 clinical testing, and then seek to out-license
or sell the program to a multinational pharmaceutical company. If
successful, the commercial opportunity for this program could be
very significant.
About Kalytera TherapeuticsKalytera
Therapeutics, Inc. ("Kalytera") is pioneering the
development of a next generation of cannabinoid therapeutics.
Through its proven leadership, drug development expertise, and
intellectual property portfolio, Kalytera seeks to establish a
leading position in the development of novel cannabinoid medicines
for a range of important unmet medical needs, with an initial focus
on graft versus host disease (“GVHD”).
- Website Home: https://kalytera.co/
- News and Insights: https://kalytera.co/news/
- Investors: https://kalytera.co/investors/
Cautionary StatementsNeither TSX Venture
Exchange nor its Regulation Services Provider (as that term is
defined in the policies of the TSX Venture Exchange) accepts
responsibility for the adequacy or accuracy of this release.
This press release may contain certain forward-looking
information and statements ("forward-looking information") within
the meaning of applicable Canadian securities legislation, that are
not based on historical fact, including without limitation in
respect of its product candidate pipeline, planned clinical trials,
regulatory approval prospects, intellectual property objectives and
other statements containing the words "believes", "anticipates",
"plans", "intends", "will", "should", "expects", "continue",
"estimate", "forecasts" and other similar expressions. Readers are
cautioned to not place undue reliance on forward-looking
information. Actual results and developments may differ materially
from those contemplated by these statements depending on, among
other things, the risk that future clinical studies may not proceed
as expected or may produce unfavourable results. Kalytera
undertakes no obligation to comment on analyses, expectations or
statements made by third-parties, its securities, or financial or
operating results (as applicable). Although Kalytera believes that
the expectations reflected in forward-looking information in this
press release are reasonable, such forward-looking information has
been based on expectations, factors and assumptions concerning
future events which may prove to be inaccurate and are subject to
numerous risks and uncertainties, certain of which are beyond
Kalytera's control. The forward-looking information contained in
this press release is expressly qualified by this cautionary
statement and is made as of the date hereof. Kalytera disclaims any
intention and has no obligation or responsibility, except as
required by law, to update or revise any forward-looking
information, whether as a result of new information, future events
or otherwise.
Contact Information
- Robert Farrell President, CEO (888) 861-2008
info@kalytera.co
- Colwell Capital Corp.Graeme
Dick1-403-561-8989graeme@colwellcapital.com
Kalytera Therapeutics (TSXV:KALY)
Historical Stock Chart
From Aug 2024 to Sep 2024
Kalytera Therapeutics (TSXV:KALY)
Historical Stock Chart
From Sep 2023 to Sep 2024